PTC Begin Period Cash Flow vs Capital Expenditures Analysis

PTCT Stock

USD 45.23 0.61 1.33%

PTC Therapeutics financial indicator trend analysis is much more than just breaking down PTC Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether PTC Therapeutics is a good investment. Please check the relationship between PTC Therapeutics Begin Period Cash Flow and its Capital Expenditures accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PTC Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.

Begin Period Cash Flow vs Capital Expenditures

Begin Period Cash Flow vs Capital Expenditures Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of PTC Therapeutics Begin Period Cash Flow account and Capital Expenditures. At this time, the significance of the direction appears to have very strong relationship.

The correlation between PTC Therapeutics' Begin Period Cash Flow and Capital Expenditures is 0.86. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of PTC Therapeutics, assuming nothing else is changed. The correlation between historical values of PTC Therapeutics' Begin Period Cash Flow and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of PTC Therapeutics are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of Begin Period Cash Flow i.e., PTC Therapeutics' Begin Period Cash Flow and Capital Expenditures go up and down completely randomly.

Correlation Coefficient

0.86

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Capital Expenditures

Capital Expenditures are funds used by PTC Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of PTC Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Most indicators from PTC Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into PTC Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PTC Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.At this time, PTC Therapeutics' Selling General Administrative is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 0.80 in 2024, whereas Enterprise Value Over EBITDA is likely to drop (11.75) in 2024.

	2021	2022	2023	2024 (projected)
Research Development	540.7M	651.5M	666.6M	699.9M
Total Revenue	538.6M	698.8M	937.8M	984.7M

Research Development Total Revenue

PTC Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Accounts Payable	Cash	Other Assets	Long Term Debt	Short Term Investments	Other Current Assets	Total Liab	Property Plant Equipment	Short Long Term Debt Total	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity
Total Assets		0.84	0.89	-0.24	0.81	0.66	0.77	0.92	0.65	0.67	0.43	0.92	0.78	0.65	0.84	0.27	0.48	-0.87	0.91	0.61	0.88	0.86	0.88	0.92	0.9	0.28
Other Current Liab	0.84		0.86	-0.56	0.39	0.41	0.6	0.73	0.86	0.29	0.82	0.91	0.62	0.85	0.87	-0.16	0.78	-0.91	0.65	0.19	0.61	0.91	0.7	0.75	0.95	0.23
Total Current Liabilities	0.89	0.86		-0.63	0.58	0.52	0.8	0.84	0.86	0.41	0.5	0.98	0.92	0.86	0.94	0.32	0.72	-0.97	0.73	0.6	0.69	0.96	0.75	0.83	0.96	0.26
Total Stockholder Equity	-0.24	-0.56	-0.63		0.16	0.0	-0.24	-0.31	-0.79	0.23	-0.57	-0.6	-0.57	-0.78	-0.67	-0.01	-0.84	0.65	-0.04	-0.09	-0.01	-0.63	-0.11	-0.23	-0.61	-0.09
Other Liab	0.81	0.39	0.58	0.16		0.61	0.55	0.82	0.17	0.83	-0.09	0.6	0.62	0.18	0.52	0.58	0.02	-0.48	0.88	0.79	0.82	0.49	0.69	0.75	0.56	0.21
Accounts Payable	0.66	0.41	0.52	0.0	0.61		0.54	0.66	0.14	0.49	0.04	0.54	0.6	0.17	0.58	0.4	-0.01	-0.56	0.73	0.64	0.57	0.59	0.71	0.75	0.5	0.3
Cash	0.77	0.6	0.8	-0.24	0.55	0.54		0.62	0.59	0.45	0.15	0.73	0.78	0.61	0.64	0.44	0.32	-0.75	0.68	0.64	0.69	0.73	0.77	0.78	0.67	0.33
Other Assets	0.92	0.73	0.84	-0.31	0.82	0.66	0.62		0.59	0.78	0.38	0.88	0.8	0.61	0.88	0.35	0.49	-0.82	0.8	0.68	0.87	0.78	0.75	0.84	0.87	0.22
Long Term Debt	0.65	0.86	0.86	-0.79	0.17	0.14	0.59	0.59		0.14	0.77	0.85	0.65	1.0	0.81	-0.09	0.95	-0.88	0.35	0.16	0.46	0.84	0.51	0.55	0.87	0.18
Short Term Investments	0.67	0.29	0.41	0.23	0.83	0.49	0.45	0.78	0.14		0.01	0.46	0.42	0.17	0.42	0.37	0.03	-0.35	0.58	0.6	0.87	0.27	0.56	0.57	0.43	0.17
Other Current Assets	0.43	0.82	0.5	-0.57	-0.09	0.04	0.15	0.38	0.77	0.01		0.59	0.17	0.75	0.6	-0.64	0.83	-0.62	0.15	-0.34	0.28	0.59	0.32	0.34	0.67	0.12
Total Liab	0.92	0.91	0.98	-0.6	0.6	0.54	0.73	0.88	0.85	0.46	0.59		0.87	0.86	0.96	0.22	0.74	-0.98	0.76	0.54	0.72	0.96	0.76	0.85	0.99	0.26
Property Plant Equipment	0.78	0.62	0.92	-0.57	0.62	0.6	0.78	0.8	0.65	0.42	0.17	0.87		0.67	0.88	0.63	0.5	-0.86	0.71	0.83	0.61	0.85	0.66	0.76	0.81	0.21
Short Long Term Debt Total	0.65	0.85	0.86	-0.78	0.18	0.17	0.61	0.61	1.0	0.17	0.75	0.86	0.67		0.83	-0.06	0.94	-0.89	0.35	0.19	0.48	0.84	0.52	0.56	0.87	0.2
Property Plant And Equipment Net	0.84	0.87	0.94	-0.67	0.52	0.58	0.64	0.88	0.81	0.42	0.6	0.96	0.88	0.83		0.22	0.74	-0.96	0.68	0.53	0.66	0.94	0.7	0.79	0.96	0.22
Current Deferred Revenue	0.27	-0.16	0.32	-0.01	0.58	0.4	0.44	0.35	-0.09	0.37	-0.64	0.22	0.63	-0.06	0.22		-0.24	-0.16	0.42	0.91	0.27	0.17	0.22	0.31	0.11	0.1
Net Debt	0.48	0.78	0.72	-0.84	0.02	-0.01	0.32	0.49	0.95	0.03	0.83	0.74	0.5	0.94	0.74	-0.24		-0.76	0.17	-0.02	0.3	0.72	0.31	0.37	0.78	0.08
Retained Earnings	-0.87	-0.91	-0.97	0.65	-0.48	-0.56	-0.75	-0.82	-0.88	-0.35	-0.62	-0.98	-0.86	-0.89	-0.96	-0.16	-0.76		-0.7	-0.48	-0.67	-0.99	-0.78	-0.84	-0.97	-0.26
Non Current Assets Total	0.91	0.65	0.73	-0.04	0.88	0.73	0.68	0.8	0.35	0.58	0.15	0.76	0.71	0.35	0.68	0.42	0.17	-0.7		0.7	0.77	0.74	0.85	0.91	0.73	0.27
Non Currrent Assets Other	0.61	0.19	0.6	-0.09	0.79	0.64	0.64	0.68	0.16	0.6	-0.34	0.54	0.83	0.19	0.53	0.91	-0.02	-0.48	0.7		0.59	0.48	0.54	0.63	0.45	0.15
Cash And Short Term Investments	0.88	0.61	0.69	-0.01	0.82	0.57	0.69	0.87	0.46	0.87	0.28	0.72	0.61	0.48	0.66	0.27	0.3	-0.67	0.77	0.59		0.61	0.86	0.85	0.7	0.22
Net Receivables	0.86	0.91	0.96	-0.63	0.49	0.59	0.73	0.78	0.84	0.27	0.59	0.96	0.85	0.84	0.94	0.17	0.72	-0.99	0.74	0.48	0.61		0.78	0.84	0.95	0.27
Common Stock Total Equity	0.88	0.7	0.75	-0.11	0.69	0.71	0.77	0.75	0.51	0.56	0.32	0.76	0.66	0.52	0.7	0.22	0.31	-0.78	0.85	0.54	0.86	0.78		0.93	0.73	0.19
Common Stock Shares Outstanding	0.92	0.75	0.83	-0.23	0.75	0.75	0.78	0.84	0.55	0.57	0.34	0.85	0.76	0.56	0.79	0.31	0.37	-0.84	0.91	0.63	0.85	0.84	0.93		0.82	0.44
Non Current Liabilities Total	0.9	0.95	0.96	-0.61	0.56	0.5	0.67	0.87	0.87	0.43	0.67	0.99	0.81	0.87	0.96	0.11	0.78	-0.97	0.73	0.45	0.7	0.95	0.73	0.82		0.27
Other Stockholder Equity	0.28	0.23	0.26	-0.09	0.21	0.3	0.33	0.22	0.18	0.17	0.12	0.26	0.21	0.2	0.22	0.1	0.08	-0.26	0.27	0.15	0.22	0.27	0.19	0.44	0.27

Click cells to compare fundamentals

PTC Therapeutics Account Relationship Matchups

PTC Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.6B	2.2B	1.9B	1.7B	1.9B	2.0B
Other Current Liab	197.3M	232.7M	60.8M	348.2M	385.9M	405.2M
Total Current Liabilities	235.9M	277.3M	509.3M	406.2M	603.1M	633.3M
Total Stockholder Equity	594.3M	482.0M	1.4M	(347.1M)	(818.6M)	(777.6M)
Other Liab	490.7M	1.0B	1.1B	269.5M	309.9M	263.2M
Accounts Payable	10.3M	18.7M	23.0M	27.3M	6.0M	9.9M
Cash	686.6M	208.8M	773.4M	410.7M	594.0M	623.7M
Other Assets	16.4M	60.6M	46.5M	33.4M	38.4M	40.3M
Long Term Debt	293.9M	309.1M	281.9M	571.7M	1.9B	2.0B
Short Term Investments	398.5M	894.8M	583.7M	130.9M	282.7M	281.6M
Other Current Assets	17.9M	78.9M	(126.3M)	105.7M	150.3M	157.8M
Total Liab	1.0B	1.7B	1.9B	2.1B	2.7B	2.8B
Property Plant Equipment	21.5M	33.8M	130.0M	72.6M	83.5M	87.7M
Short Long Term Debt Total	313.9M	420.4M	441.7M	703.6M	2.2B	2.3B
Property Plant And Equipment Net	21.5M	118.2M	130.0M	175.0M	179.0M	187.9M
Current Deferred Revenue	8.2M	4.2M	265.8M	1.4M	801K	761.0K
Net Debt	(372.7M)	211.6M	(341.9M)	292.9M	1.6B	1.7B
Retained Earnings	(1.2B)	(1.6B)	(2.1B)	(2.7B)	(3.3B)	(3.1B)
Non Current Assets Total	844.5M	976.5M	1.2B	1.0B	677.1M	479.9M
Non Currrent Assets Other	30.1M	60.6M	227.5M	48.6M	36.2M	34.8M
Cash And Short Term Investments	686.6M	1.1B	773.4M	410.7M	876.7M	450.9M
Net Receivables	55.5M	69.9M	110.5M	155.6M	161.0M	169.1M
Common Stock Total Equity	62K	70K	71K	72K	82.8K	45.3K
Common Stock Shares Outstanding	58.9M	66.0M	70.5M	71.7M	74.8M	49.7M
Liabilities And Stockholders Equity	1.6B	2.2B	1.9B	1.7B	1.9B	1.0B
Non Current Liabilities Total	793.6M	1.4B	1.2B	1.6B	2.1B	2.2B
Other Stockholder Equity	1.8B	2.2B	2.1B	2.3B	2.5B	2.6B
Property Plant And Equipment Gross	21.5M	118.2M	157.2M	212.4M	230.3M	241.8M
Total Current Assets	779.3M	1.2B	773.4M	693.8M	1.2B	1.3B
Accumulated Other Comprehensive Income	(10.6M)	(61.0M)	(24.3M)	4.8M	(1.3M)	(1.3M)
Short Term Debt	20M	17.5M	159.8M	24.7M	210.3M	220.8M
Common Stock	62K	70K	71K	72K	75K	48.1K
Net Tangible Assets	(198.5M)	(315.7M)	(805.7M)	(1.1B)	(1.0B)	(970.7M)
Retained Earnings Total Equity	(1.2B)	(1.6B)	(2.1B)	(2.7B)	(2.4B)	(2.3B)
Capital Surpluse	1.8B	2.2B	2.1B	2.3B	2.7B	1.6B
Inventory	19.3M	18.7M	15.9M	21.8M	30.6M	32.1M
Deferred Long Term Liab	130.9M	136.7M	137.1M	102.8M	118.3M	70.3M
Non Current Liabilities Other	368.9M	1.0B	1.0B	971.9M	141K	134.0K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for PTC Stock Analysis

When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC